drugset / Trial / NCT01926158

Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women

NCT01926158

Phase 4 Completed 65 enrolled Turku University Hospital Amgen · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This randomized clinical trial will evaluate the efficacy of an antiresorptive osteoporosis drug (denosumab) in prevention of periprosthetic bone loss and in promotion of implant osseointegration (bone bonding) in postmenopausal women after total hip replacement. The investigators assume that denosumab prevents periprosthetic bone loss and enhances bone bonding of the hip stem in postmenopausal women.

Timeline

Start
2013-12
Primary completion
2017-02-04
Completion
2017-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous

Indications